Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Roche Media News
Get the latest updates from Roche Media News directly as they happen.
Follow now 329 followers
Latest posts
Last updated 1 day ago
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
1 day ago
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at...
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
2 days ago
Petrelintide achieved up to 10.7% mean body weight reduction at week 42...
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)
6 days ago
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses...
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
16 days ago
Filing acceptance based on phase III data showing giredestrant plus everolimus reduced...
Change to the Roche Enlarged Corporate Executive Committee
19 days ago
Basel, 17 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today...
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
20 days ago
MAJESTY, the first global phase III study in primary membranous nephropathy, met...
Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
28 days ago
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
about 1 month ago
Group sales grew by 7%1 at constant exchange rates (CER; 2% in...
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
about 1 month ago
A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight...
FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
3 months ago
Lunsumio VELO reduces administration time from 2-4 hours to approximately one minuteAvailability...
Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu
3 months ago
With this approval, Roche’s automated mass spectrometry platform now offers the industry’s...
Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
3 months ago
Giredestrant is the only oral SERD to show superior invasive disease-free survival...